Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $139.18M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 4.34M
Average 8.14M
HUMA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Humacyte, Inc.NASDAQ: HUMA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $19.46M rose 26.2% year over year, ahead of the -11.4% change in trailing-twelve-month research & development. Sequentially, it rose 33.3% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Research & development amounted to 3400.5% of revenue in FY2025.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +26.2% holds above the trailing-twelve-month pace of -11.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 69.3M USD
- Year-over-year change
- -21.8%
- 4-year CAGR
- +3.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 69.3M | -21.8% |
| FY2024 | 2024-12-31 | 88.6M | +15.7% |
| FY2023 | 2023-12-31 | 76.55M | +21.0% |
| FY2022 | 2022-12-31 | 63.26M | +3.1% |
| FY2021 | 2021-12-31 | 61.34M | — |
Research & Development vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 research & development of $73.35M is the 8th highest of the 11 companies compared; the peer median is $100.12M.
- Its year-over-year change of -11.4% is the 7th highest of 11, against a peer median of -6.2%.
- Research & development amounts to 3638.2% of revenue for HUMA, versus a peer median of 290.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $40.3M | -12.6% | +4.1% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $30.71M | -36.7% | +16.2% | — |
| LTM Mar 2026 | $19.19M | -29.2% | -8.6% | — | |
| Peer median (excluding HUMA) | $100.12M | -6.2% | +6.7% | 290.9% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| Weighted Avg Shares | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
| Weighted Avg Shares (Diluted) | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.